# SAvvyWire™ EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI)

Study · id `cardio:ct-nct05492383` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05492383](<https://clinicaltrials.gov/study/NCT05492383>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05492383

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.

## Technical summary

Registry record NCT05492383. Allocation not applicable; no masking; primary purpose other. Start 2022-10-25 (actual); primary completion 2023-03-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 119 participants (enrolled count; ClinicalTrials.gov record NCT05492383, source copy `cardio:ctgov-nct05492383-2023-04-12`, retrieved 2026-10-26)
- Started: 2022-10-25 (actual) (ClinicalTrials.gov record NCT05492383, source copy `cardio:ctgov-nct05492383-2023-04-12`, retrieved 2026-10-26)
- Primary completion: 2023-03-03 (actual) (ClinicalTrials.gov record NCT05492383, source copy `cardio:ctgov-nct05492383-2023-04-12`, retrieved 2026-10-26)
- Completion: 2023-03-03 (actual) (ClinicalTrials.gov record NCT05492383, source copy `cardio:ctgov-nct05492383-2023-04-12`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT05492383, source copy `cardio:ctgov-nct05492383-2023-04-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05492383-2023-04-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: SAvvyWire™ EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI)
- Acronym: SAFE-TAVI
- Condition: Severe Aortic Stenosis
- Intervention (Device): TAVI
- Lead sponsor: Opsens, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: c622dbdabcd46f3f7bc954f0112500200a214bd01e7f73e5487cd6152da329b5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
